Lung Squamous Cell CarcinomaPhase 2NCT07618793
Intermittent Hypoxic Training as Neoadjuvant Therapy for Lung Squamous Cell Carcinoma
A Phase 2 study testing Intermittent Hypoxic Training (IHT) and Standard Neoadjuvant Chemo-immunotherapy in people with Lung Squamous Cell Carcinoma and Carcinoma, Non-Small-Cell Lung (NSCLC), run by zhang yi at 1 site in China.
Trial summary
The goal of this clinical trial is to learn if adding intermittent hypoxic training (IHT) to standard neoadjuvant chemo-immunotherapy can increase the pathologic complete response (pCR) rate in patients aged 18 to 75 of both sexes with resectable stage II-IIIA lung squamous cell carcinoma. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Lung Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung (NSCLC)
- What is being tested?
- Intermittent Hypoxic Training (IHT) and Standard Neoadjuvant Chemo-immunotherapy
- Type of treatment
- Injection or infusion, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteChina
- Study dates
- Jun 2026to Dec 2028
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age between 18 and 75 years old (inclusive), regardless of sex.
- Diagnosed with histologically confirmed stage II-IIIA (according to the AJCC 8th edition staging system) squamous cell lung carcinoma.
- The primary tumor is evaluated by a multidisciplinary team (MDT) and deemed completely resectable.
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
- Life expectancy of at least 6 months.
- Adequate organ, bone marrow, and coagulation functions, meeting the following laboratory criteria within 7 days prior to enrollment:
Show all 15Show fewer
- Absolute neutrophil count (ANC) >= 1.5 x 10^9/L;
- Platelet count >= 100 x 10^9/L;
- Hemoglobin >= 90 g/L;
- Total bilirubin <= 1.5 x upper limit of normal (ULN);
- Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) <= 2.5 x ULN;
- Serum creatinine <= 1.5 x ULN, or creatinine clearance >= 50 mL/min;
- International normalized ratio (INR) and activated partial thromboplastin time (APTT) <= 1.5 x ULN.
- Female participants of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose and agree to use effective contraception during the study and for at least 6 months after the last dose. Male participants must agree to use effective contraception during the study and for at least 6 months after the last dose.
- Participant understands the study protocol, voluntarily participates, and signs the written Informed Consent Form (ICF).
Who cannot join
- Histologically confirmed small cell lung cancer, adeno-squamous carcinoma, large cell neuroendocrine carcinoma, or adenocarcinoma (including components of these types).
- Patients with driver gene mutations that have approved targeted therapies available (e.g., EGFR mutations, ALK rearrangements, ROS1 fusions, etc.).
- Prior systemic antitumor therapy for lung cancer, including chemotherapy, radiotherapy, immunotherapy, targeted therapy, or definitive surgical resection.
- Active, known, or suspected autoimmune diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, autoimmune hepatitis), or a history of autoimmune disease within the past 2 years.
- History of other malignant tumors within the past 5 years, except for adequately treated cured skin basal cell carcinoma, squamous cell carcinoma, or carcinoma in situ (e.g., cervical carcinoma in situ).
- Severe cardiovascular or cerebrovascular diseases, including but not limited to:
Show all 18Show fewer
- Myocardial infarction or unstable angina within the past 6 months;
- New York Heart Association (NYHA) Class III or IV congestive heart failure;
- Clinically significant ventricular arrhythmia or poorly controlled symptomatic arrhythmia;
- Stroke or transient ischemic attack (TIA) within the past 6 months.
- Poorly controlled hypertension (systolic blood pressure >= 160 mmHg and/or diastolic blood pressure >= 100 mmHg despite standard antihypertensive therapy).
- Chronic obstructive pulmonary disease (COPD) or other respiratory diseases with severe lung function impairment (e.g., FEV1 < 50% predicted value, or requiring long-term home oxygen therapy).
- Active infections requiring systemic intravenous anti-infective treatment within 2 weeks prior to enrollment (e.g., severe pneumonia, bacteremia), or active tuberculosis infection.
- Known history of human immunodeficiency virus (HIV) infection, or active Hepatitis B (HBV DNA >= 500 IU/mL or copy number above detection limit) or active Hepatitis C (HCV RNA positive).
- History of interstitial lung disease (ILD), drug-induced pneumonitis, radiation pneumonitis requiring steroid treatment, or evidence of active pneumonitis.
- Severe claustrophobia, severe high-altitude sickness history, or other medical/psychological conditions that prevent compliance with intermittent hypoxic training (IHT) using the FLY-2265 low oxygen system.
- Pregnant or breastfeeding women.
- Any other medical condition, clinical laboratory abnormality, or social circumstance that, in the opinion of the investigator, may compromise participant safety, interfere with the evaluation of study interventions, or affect compliance with study procedures.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
Xuanwu Hospital, Capital Medical University
Beijing, Beijing Municipality, 100053
Yi Zhang, PhD, +86-13141370703, zhangyixwhosp@xwh.ccmu.edu.cn
About this study
Official title: Study on the Novel Application of Intermittent Hypoxic Training in Neoadjuvant Therapy for Lung Squamous Cell Carcinoma
The goal of this clinical trial is to learn if adding intermittent hypoxic training (IHT) to standard neoadjuvant chemo-immunotherapy can increase the pathologic complete response (pCR) rate in patients aged 18 to 75 of both sexes with resectable stage II-IIIA lung squamous cell carcinoma. The main questions it aims to answer are:Can the addition of IHT to standard neoadjuvant chemo-immunotherapy significantly improve the pathologic complete response (pCR) rate compared to standard therapy alone? Is IHT safe and well-tolerated in this perioperative setting, and can it improve 2-year recurrence-free survival (RFS) without increasing complications? Researchers will compare the experimental group (standard neoadjuvant chemo-immunotherapy combined with IHT) to the control group (standard neoadjuvant chemo-immunotherapy alone) to see if the combination safely enhances anti-tumor immune responses, improves tumor regression, and extends long-term survival. Participants will:Receive standard neoadjuvant chemo-immunotherapy for 4 cycles (21 days per cycle), consisting of nab-paclitaxel, carboplatin, and pembrolizumab. Undergo Intermittent Hypoxic Training (IHT) if randomized to the experimental group, using the FLY-2265 low oxygen system (13% $FiO_2$ for 5 minutes followed by 21% $FiO_2$ for 5 minutes per cycle; 10 cycles per session, twice daily) for 7 consecutive days starting on Day 1 of each chemo-immunotherapy cycle. Undergo surgery (VATS lobectomy and systematic lymph node dissection) 3 to 4 weeks after the completion of the 4th cycle, provided that the disease has not progressed. Complete regular post-operative follow-up visits (including chest CT scans, brain MRIs, bone scans, tumor markers, and peripheral blood immune monitoring) for up to 5 years to evaluate long-term outcomes.
- Being tested
- Intermittent Hypoxic Training (IHT), Standard Neoadjuvant Chemo-immunotherapy
- Keywords
- Lung Squamous Cell Carcinoma, Intermittent Hypoxic Training, Neoadjuvant Chemoimmunotherapy, CD8-Positive T-Lymphocytes, Non-Small Cell Lung Cancer, Pathologic Complete Response
- Medical subject headings
- Carcinoma, Carcinoma, Non-Small-Cell Lung, Pathologic Complete Response
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Intermittent Hypoxic Training (IHT)Device
Participants will undergo Intermittent Hypoxic Training (IHT) using the FLY-2265 low oxygen system. The training protocol consists of cycles of inhaling 13% FiO2 (fraction of inspired oxygen) for 5 minutes, followed by 21% FiO2 (room air) for 5 minutes. Each session comprises 10 cycles, administered twice daily, for 7 consecutive days. This 7-day training course starts on Day 1 of each 21-day neoadjuvant treatment cycle, for a total of 4 courses.
Standard Neoadjuvant Chemo-immunotherapyCombination product
Also called Nab-paclitaxel, Carboplatin, Pembrokizumab
Participants will receive standard clinical doses of neoadjuvant chemo-immunotherapy for 4 cycles (21 days per cycle) prior to surgery. The regimen includes: 1) Nab-paclitaxel; 2) Carboplatin; 3) Pembrolizumab. All agents will be administered via intravenous infusion according to standard clinical oncology guidelines.
| Study group | Role | What they receive |
|---|---|---|
| Intermittent Hypoxic Training + Chemo-immunotherapy | Experimental | Participants will receive standard neoadjuvant chemo-immunotherapy (nab-paclitaxel + carboplatin + pembrolizumab) for 4 cycles (21 days per cycle). Concurrently, participants will undergo Intermittent Hypoxic Training (IHT) using the FLY-2265 system (13% FiO2 for 5 min, 21% FiO2 for 5 min per cycle; 10 cycles/session, twice daily) for 7 consecutive days starting on Day 1 of each chemo-immunotherapy cycle. Surgery will be performed 3-4 weeks after completing the 4th cycle. Receives: Device: Intermittent Hypoxic Training (IHT); Combination Product: Standard Neoadjuvant Chemo-immunotherapy |
| Standard Neoadjuvant Chemo-immunotherapy Alone | Active comparator | Participants will receive standard neoadjuvant chemo-immunotherapy alone for 4 cycles (21 days per cycle). The regimen consists of nab-paclitaxel, carboplatin, and pembrolizumab at standard clinical doses, identical to the experimental group. No intermittent hypoxic training will be administered. Surgery will be performed 3-4 weeks after completing the 4th cycle. Receives: Combination Product: Standard Neoadjuvant Chemo-immunotherapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pathologic Complete Response (pCR) Rate
The percentage of participants who achieve pathologic complete response, defined as the complete disappearance of all invasive tumor cells in the completely resectable lung cancer specimen and all sampled regional lymph nodes (ypT0N0) following neoadjuvant therapy.
Measured: At the time of surgery (approximately 3 to 4 weeks after the completion of the 4th cycle of neoadjuvant therapy).
Secondary outcomes (4)
Major Pathological Response (MPR) Rate
The percentage of participants with 10% or less viable tumor cells remaining in the resected primary tumor specimen following neoadjuvant therapy.
Measured: At the time of surgery (approximately 3 to 4 weeks after the completion of the 4th cycle of neoadjuvant therapy).
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Safety and tolerability evaluated by grading and recording adverse events, compliance with intermittent hypoxic training, and delay or discontinuation of neoadjuvant therapy, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
Measured: From the start of neoadjuvant therapy up to 30 days after surgery (approximately 5 months).
2-Year Recurrence-Free Survival (RFS) Rate
The percentage of participants who are alive without tumor recurrence or progression at 2 years after surgery.
Measured: 2 years post-surgery.
Changes in Peripheral Blood Immune Cell Subsets
Evaluation of tumor immune microenvironment factors and systemic immunity, including the percentage of CD8+ T cells, CD4+ T cells, and the CD4+/CD8+ T-cell ratio measured by flow cytometry.
Measured: Baseline (before therapy) and prior to surgery (approximately 12 weeks after baseline).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Jun 2026
- Study startJun 2026 (estimated)
- Primary completionDec 2027 (estimated)
- Study completionDec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung Squamous Cell CarcinomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This is a prospective, randomized, open-label, parallel-controlled, single-center clinical trial. Eligible participants with resectable stage II-IIIA lung squamous cell carcinoma will be randomly assigned in a 1:1 ratio to either the experimental group (receiving standard neoadjuvant chemo-immunotherapy combined with intermittent hypoxic training) or the control group (receiving standard neoadjuvant chemo-immunotherapy alone).
- Masking
- None (open label)
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- zhang yi
- Sponsor type
- University, hospital or other
- Collaborators
- Capital Medical University
- Responsible party
- Sponsor-investigator, zhang yi, Xuanwu Hospital, Beijing
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07618793
- Sponsor's protocol ID
- KS2026139
- Other IDs
- CFH-2026-2-2014
- Status last verified
- May 2026
- First submitted
- 25 May 2026
- Last updated
- 1 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study on the Novel Application of Intermittent Hypoxic Training in Neoadjuvant Therapy for Lung Squamous Cell Carcinoma
- ClinicalTrials.gov ID
- NCT07618793
- Acronym / sponsor ID
- KS2026139
- Keywords
- Lung Squamous Cell Carcinoma, Intermittent Hypoxic Training, Neoadjuvant Chemoimmunotherapy, CD8-Positive T-Lymphocytes, Non-Small Cell Lung Cancer, Pathologic Complete Response
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- zhang yiUniversity, hospital or other
- Collaborators
- Capital Medical University
- Study start
- Jun 2026 (estimated)
- Primary completion
- Dec 2027 (estimated)
- Study completion
- Dec 2028 (estimated)
- First posted
- 1 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn if adding intermittent hypoxic training (IHT) to standard neoadjuvant chemo-immunotherapy can increase the pathologic complete response (pCR) rate in patients aged 18 to 75 of both sexes with resectable stage II-IIIA lung squamous cell carcinoma. The main questions it aims to answer are:Can the addition of IHT to standard neoadjuvant chemo-immunotherapy significantly improve the pathologic complete response (pCR) rate compared to standard therapy alone? Is IHT safe and well-tolerated in this perioperative setting, and can it improve 2-year recurrence-free survival (RFS) without increasing complications? Researchers will compare the experimental group (standard neoadjuvant chemo-immunotherapy combined with IHT) to the control group (standard neoadjuvant chemo-immunotherapy alone) to see if the combination safely enhances anti-tumor immune responses, improves tumor regression, and extends long-term survival. Participants will:Receive standard neoadjuvant chemo-immunotherapy for 4 cycles (21 days per cycle), consisting of nab-paclitaxel, carboplatin, and pembrolizumab. Undergo Intermittent Hypoxic Training (IHT) if randomized to the experimental group, using the FLY-2265 low oxygen system (13% $FiO_2$ for 5 minutes followed by 21% $FiO_2$ for 5 minutes per cycle; 10 cycles per session, twice daily) for 7 consecutive days starting on Day 1 of each chemo-immunotherapy cycle. Undergo surgery (VATS lobectomy and systematic lymph node dissection) 3 to 4 weeks after the completion of the 4th cycle, provided that the disease has not progressed. Complete regular post-operative follow-up visits (including chest CT scans, brain MRIs, bone scans, tumor markers, and peripheral blood immune monitoring) for up to 5 years to evaluate long-term outcomes.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- This is a prospective, randomized, open-label, parallel-controlled, single-center clinical trial. Eligible participants with resectable stage II-IIIA lung squamous cell carcinoma will be randomly assigned in a 1:1 ratio to either the experimental group (receiving standard neoadjuvant chemo-immunotherapy combined with intermittent hypoxic training) or the control group (receiving standard neoadjuvant chemo-immunotherapy alone).
| Arm | Type | Receives |
|---|---|---|
| Intermittent Hypoxic Training + Chemo-immunotherapy | Experimental | Device: Intermittent Hypoxic Training (IHT), Combination Product: Standard Neoadjuvant Chemo-immunotherapyParticipants will receive standard neoadjuvant chemo-immunotherapy (nab-paclitaxel + carboplatin + pembrolizumab) for 4 cycles (21 days per cycle). Concurrently, participants will undergo Intermittent Hypoxic Training (IHT) using the FLY-2265 system (13% FiO2 for 5 min, 21% FiO2 for 5 min per cycle; 10 cycles/session, twice daily) for 7 consecutive days starting on Day 1 of each chemo-immunotherapy cycle. Surgery will be performed 3-4 weeks after completing the 4th cycle. |
| Standard Neoadjuvant Chemo-immunotherapy Alone | Active comparator | Combination Product: Standard Neoadjuvant Chemo-immunotherapyParticipants will receive standard neoadjuvant chemo-immunotherapy alone for 4 cycles (21 days per cycle). The regimen consists of nab-paclitaxel, carboplatin, and pembrolizumab at standard clinical doses, identical to the experimental group. No intermittent hypoxic training will be administered. Surgery will be performed 3-4 weeks after completing the 4th cycle. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (15 listed)
- Age between 18 and 75 years old (inclusive), regardless of sex.
- Diagnosed with histologically confirmed stage II-IIIA (according to the AJCC 8th edition staging system) squamous cell lung carcinoma.
- The primary tumor is evaluated by a multidisciplinary team (MDT) and deemed completely resectable.
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
- Life expectancy of at least 6 months.
Key exclusion criteria (18 listed)
- Histologically confirmed small cell lung cancer, adeno-squamous carcinoma, large cell neuroendocrine carcinoma, or adenocarcinoma (including components of these types).
- Patients with driver gene mutations that have approved targeted therapies available (e.g., EGFR mutations, ALK rearrangements, ROS1 fusions, etc.).
- Prior systemic antitumor therapy for lung cancer, including chemotherapy, radiotherapy, immunotherapy, targeted therapy, or definitive surgical resection.
- Active, known, or suspected autoimmune diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, autoimmune hepatitis), or a history of autoimmune disease within the past 2 years.
- History of other malignant tumors within the past 5 years, except for adequately treated cured skin basal cell carcinoma, squamous cell carcinoma, or carcinoma in situ (e.g., cervical carcinoma in situ).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Intermittent Hypoxic Training (IHT)Participants will undergo Intermittent Hypoxic Training (IHT) using the FLY-2265 low oxygen system. The training protocol consists of cycles of inhaling 13% FiO2 (fraction of inspired oxygen) for 5 minutes, followed by 21% FiO2 (room air) for 5 minutes. Each session comprises 10 cycles, administered twice daily, for 7 consecutive days. This 7-day training course starts on Day 1 of each 21-day neoadjuvant treatment cycle, for a total of 4 courses. | Device | Intermittent Hypoxic Training + Chemo-immunotherapy |
| Standard Neoadjuvant Chemo-immunotherapyAlso: Nab-paclitaxel, Carboplatin, PembrokizumabParticipants will receive standard clinical doses of neoadjuvant chemo-immunotherapy for 4 cycles (21 days per cycle) prior to surgery. The regimen includes: 1) Nab-paclitaxel; 2) Carboplatin; 3) Pembrolizumab. All agents will be administered via intravenous infusion according to standard clinical oncology guidelines. | Combination product | Intermittent Hypoxic Training + Chemo-immunotherapy, Standard Neoadjuvant Chemo-immunotherapy Alone |
Primary outcome
Pathologic Complete Response (pCR) Rate
Time frame: At the time of surgery (approximately 3 to 4 weeks after the completion of the 4th cycle of neoadjuvant therapy).
The percentage of participants who achieve pathologic complete response, defined as the complete disappearance of all invasive tumor cells in the completely resectable lung cancer specimen and all sampled regional lymph nodes (ypT0N0) following neoadjuvant therapy.
4 secondary outcomes
Major Pathological Response (MPR) Rate
Time frame: At the time of surgery (approximately 3 to 4 weeks after the completion of the 4th cycle of neoadjuvant therapy).
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Time frame: From the start of neoadjuvant therapy up to 30 days after surgery (approximately 5 months).
2-Year Recurrence-Free Survival (RFS) Rate
Time frame: 2 years post-surgery.
Changes in Peripheral Blood Immune Cell Subsets
Time frame: Baseline (before therapy) and prior to surgery (approximately 12 weeks after baseline).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for Lung Squamous Cell Carcinoma
RecruitingPhase 3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
RecruitingPhase 2
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Solid Tumors
RecruitingPhase 3
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Non Small Cell Lung Cancer, c-MET
RecruitingPhase 3
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma
RecruitingPhase 3
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Non-small Cell Lung Cancer, NSCLC
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Intermittent Hypoxic Training (IHT) and Standard Neoadjuvant Chemo-immunotherapy in people with Lung Squamous Cell Carcinoma and Carcinoma, Non-Small-Cell Lung (NSCLC), run by zhang yi at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 15 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 1 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Yi Zhang, PhD (+86-13141370703, zhangyixwhosp@xwh.ccmu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pathologic Complete Response (pCR) Rate (time frame: At the time of surgery (approximately 3 to 4 weeks after the completion of the 4th cycle of neoadjuvant therapy).). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jun 2026.